Lilly 3Q Revenues: $9.5 billion (+37%) 3Q Loss: $57.4 million (earnings were $1.5 billion 3Q22) YTD Revenues: $24.8 billion (+17%) YTD Earnings: $3.1 billion (-29%)  Comments: Growth in the quarter driven by Mounjaro with sales of $1.4 billion, Verzenio, up 68% to $1.0 billion, and Jardiance, up 22% to $700.8 million, as well as $1.4 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Taltz sales were up 9% to $744.2 million. Humalog sales were down 12% to $395.4 million...